Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in MSALikeFollowShareShare your feedbackQuestions (0)Post questionYour question will be sent privately to Alterity Therapeutics. The company may choose to make this question public.Start the conversationAsk Alterity Therapeutics a question about this update.DiscoverShare your feedbackDiscover